A Delaware federal judge on Feb. 16 overturned a massive $2.5 billion jury verdict against Gilead Sciences Inc., finding that a patent held by a unit of Merck & Co. Inc. was too broad to be valid.

The ruling from U.S. District Chief Judge Leonard P. Stark of the District of Delaware reversed a federal jury’s finding in 2016 that Gilead had willfully infringed on Idenix Pharmaceutical’s patent, which discloses a “groundbreaking” treatment for hepatitis C. The verdict was the largest-ever reported in a patent, according to defense counsel in the case.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]